Slow-releasing acipimox capsule

A technology of slow-release capsules and slow-release materials, applied in the field of medicine, can solve the problems of diabetes and gout patients with aggravated conditions, poor safety, and influence on glucose and uric acid metabolism pathways, and achieve convenient administration, reduced toxic and side effects, and extensive social benefits and economical effects

Inactive Publication Date: 2005-06-15
LUNAN PHARMA GROUP CORPORATION
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the safety of clinical use is relatively poor. In addition to nausea, abdominal pain, flushing, and skin itching, it can also affect the metabolic pathways of glucose and uric acid, aggravating the condition of patients with diabetes and gout.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Slow-releasing acipimox capsule
  • Slow-releasing acipimox capsule
  • Slow-releasing acipimox capsule

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0044] (1) Preparation of pill-containing core

[0045] Acipimox 190g

[0046] Blank pellet core 300g

[0047] 7% PVP solution (90% ethanol solvent) 200g

[0048] Preparation Process:

[0049] Pass acipimox through a 160-mesh sieve, weigh the prescription, and pour it into the lower hopper. Open the granulation coating machine, enter the air pressure 0.5bar, CYL 3bar, CAP1 0.8bar, pour into the blank pellet core, and granulate. The feeding speed is 4rpm, the peristaltic pump is 12%, the rotating speed of the turntable is 145rpm, sprayed with 7% PVP solution (solvent is 90% ethanol), and dried at 50°C. The granulation is finished and 500g is discharged.

[0050](2) Eight specific prescriptions are as follows: (Determine the type and quantity of sustained-release agents)

[0051] Prescription A:

[0052] Containing pill core 500g

[0053] Ethyl cellulose 5g

[0054] Stearic acid 30g

[0055] P...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to medical technology, in particular to an acipimox sustained-release capsule. It is made up of acipimox, blank ball core, sustained-release agent, plasticizer, anti-tack agent, and the weight ratio of acipimox to blank ball core, slow-release agent anti-tack agent is 100:115:(0.4~ 40): (0~25), use ethanol to mix slurry, and the antisticking agent is 1% of ethanol weight. The preparation process adopts a granule coating mechanism to contain the pill core, and after drying, it is coated with a slow-release coating layer and blast-dried. Put it into a hard capsule shell. The invention provides an acipimox sustained-release capsule, which is a high-efficiency and safe blood lipid regulating drug, which can be released slowly to maintain a relatively stable blood drug concentration and a longer action time, and has the advantages of reduced toxic and side effects and more convenient administration .

Description

Technical field [0001] The invention belongs to medical technology, in particular a sustained-release acipimox capsule, which is an efficient and safe blood lipid regulating drug. Background technique [0002] In recent years, as dietary habits have changed, living standards have improved, and work pressure has increased, there have been more and more patients with hyperlipidemia and hyperproteinemia, and the patient population has become younger and younger. Hyperlipidemia and hyperproteinemia are a group of clinically common disorders of lipid metabolism. When the plasma lipid concentration exceeds the upper limit of the normal value, it is called hyperlipemia, and the plasma lipoprotein exceeds the normal value. High limit is called hyperlipoproteinemia (Hyperlipoproteinemia). Epidemiological studies have shown that increased levels of plasma low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) are important factors for premature atherosclerosis and coronary h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/52A61K31/4965A61P3/06
Inventor 孙勇
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap